Form 4: Executive Granted Shares Amidst Merger Termination

Cross Country Healthcare's General Counsel, Susan E. Ball, received a grant of 35,804 restricted shares following the termination of a merger agreement.

Summary

• Susan E. Ball, General Counsel and Secretary of Cross Country Healthcare, Inc. (CCRN), acquired 35,804 restricted shares of common stock.
• The transaction date for this acquisition is December 18, 2025.
• These restricted shares will vest in three substantially equal installments on December 18, 2026, March 31, 2027, and March 31, 2028.
• The Compensation Committee of the Company's Board of Directors approved the grant date of December 18, 2025, which was adjusted from an earlier planned date of March 31, 2025.
• This adjustment followed the termination of the Merger Agreement with Aya Holdings II Inc., Spark Merger Sub One Inc., and Aya Healthcare, Inc. on December 3, 2025.
• Following this transaction, Susan E. Ball's beneficial ownership of common stock will be 211,836 shares.

Sentiment

Score: 4

Explanation: The termination of a significant merger agreement represents a strategic setback for the company. While the grant of restricted shares to a key executive is a positive for individual retention and aligns interests, it occurs in the context of a failed transaction and a delayed grant, indicating underlying challenges rather than strong positive momentum.

Positives

• Grant of 35,804 restricted shares to a key executive, Susan E. Ball, which aligns her long-term interests with those of shareholders.
• The multi-year vesting schedule (2026-2028) indicates a strategy for long-term retention of a senior executive.

Negatives

• The grant date for the restricted shares was adjusted due to the termination of a significant merger agreement, indicating a failed strategic initiative.

Risks

• The termination of the merger agreement with Aya Holdings II Inc., Spark Merger Sub One Inc., and Aya Healthcare, Inc. on December 3, 2025, represents a failed strategic transaction, which could impact the company's future growth prospects, strategic direction, and market perception.

Future Outlook

The filing does not provide explicit forward-looking statements or guidance beyond the vesting schedule of the granted restricted shares, which extends through March 2028.

Management Comments

• The Compensation Committee of the Company's Board of Directors approved the number of RSAs to be granted on December 18, 2025, instead of March 31, 2025, following the termination of the Merger Agreement with Aya Holdings II Inc., Spark Merger Sub One Inc. and Aya Healthcare, Inc. on December 3, 2025.

Industry Context

The termination of a merger agreement, as noted in the filing, can signal a shift in strategic direction or challenges in market conditions within the healthcare staffing industry. The subsequent grant of restricted shares to a key executive may be a move to retain talent and stabilize leadership following the failed transaction.

Corporate Governance

Stakeholder Impact

• Shareholders: Potential impact from the terminated merger agreement, which could affect future growth and stock performance. The executive share grant aligns management interests with shareholders over the long term.
• Employees: The termination of a merger could create uncertainty, though the executive retention suggests stability at the top.
• Management: Susan E. Ball benefits directly from the share grant, providing long-term incentive.

Next Steps

• First vesting installment of restricted shares on December 18, 2026.
• Second vesting installment of restricted shares on March 31, 2027.
• Third vesting installment of restricted shares on March 31, 2028.

Key Dates

Recommendation

The termination of a significant merger agreement is a negative event that could impact the company's strategic direction and growth prospects. While the grant of restricted shares to a key executive is a positive for retention and aligns interests, it does not fully offset the strategic setback. Investors should hold and monitor for further clarity on the company's post-merger strategy and financial performance.

Keywords

Cross Country Healthcare, CCRN, Form 4, Insider Transaction, Restricted Stock, Executive Compensation, Merger Termination, Susan E. Ball, Corporate Governance